Pfizer drops antitrust claims against Johnson & Johnson over Remicade
MLex Summary: Pfizer has agreed to dismiss its claims accusing Johnson & Johnson of stifling competition through the use of exclusionary contracts to maintain its monopoly over the biologic infliximab, or...To view the full article, register now.
Already a subscriber? Click here to view full article